In this Commentary we aim to provide an overview of some specific examples of cancer therapeutics, including targeted approaches using monoclonal antibodies and kinase inhibitors, as well as highlight novel approaches for enhancing immunological responses against tumors. We point out that a fundamental property of the cancer cell, genomic instability, confounds the targeted therapies that aim to induce cell death directly while simultaneously enhancing the potential for immunological attack by creating a large number of neoantigens. We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoi...
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak ...
Recent work has suggested involvement of the immune system in biological therapies specifically targ...
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak ...
Conventional chemotherapeutics and targeted antineoplastic agents have been developed based on the s...
Cancer immunotherapy has revolutionized the oncology field, but many patients still do not respond t...
Immunotherapy is widely regarded to have the ability to transform the treatment of cancer, with immu...
Immuno-oncology (I-O) is a young and growing field on the frontier of cancer therapy. Contrary to ca...
Tumors can acquire mutations or hijack regulatory pathways of the host immune system to render them ...
Cancer cells have developed numerous ways to escape immune surveillance and gain unlimited prolifera...
The concept of cancer immunotherapy stems from the proposed function of the immune system, called im...
The genetic and cellular alterations that define cancer provide the immune system with the means to ...
Abstract Malignant cells have the capacity to rapidly grow exponentially and spread in part by suppr...
Cancer immunotherapy, including immune checkpoint blockade and adoptive CAR T-cell therapy, has clea...
By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated effi...
The immune system actively counteracts the tumorigenesis process; a breakout of the immune system fu...
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak ...
Recent work has suggested involvement of the immune system in biological therapies specifically targ...
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak ...
Conventional chemotherapeutics and targeted antineoplastic agents have been developed based on the s...
Cancer immunotherapy has revolutionized the oncology field, but many patients still do not respond t...
Immunotherapy is widely regarded to have the ability to transform the treatment of cancer, with immu...
Immuno-oncology (I-O) is a young and growing field on the frontier of cancer therapy. Contrary to ca...
Tumors can acquire mutations or hijack regulatory pathways of the host immune system to render them ...
Cancer cells have developed numerous ways to escape immune surveillance and gain unlimited prolifera...
The concept of cancer immunotherapy stems from the proposed function of the immune system, called im...
The genetic and cellular alterations that define cancer provide the immune system with the means to ...
Abstract Malignant cells have the capacity to rapidly grow exponentially and spread in part by suppr...
Cancer immunotherapy, including immune checkpoint blockade and adoptive CAR T-cell therapy, has clea...
By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated effi...
The immune system actively counteracts the tumorigenesis process; a breakout of the immune system fu...
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak ...
Recent work has suggested involvement of the immune system in biological therapies specifically targ...
The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak ...